glp-1 eye The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review GLP-1 Drugs and Diabetic Eye
Description
Mulvihill EE, Drucker DJ
An accompanying editorial to the study noted that if the benefit is cumulative, adding roughly three motor-score points of protection per year over 5-10 years, then this class of drugs could prove transformative for a disease that currently has few disease-modifying interventions
It is worth it
The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an endothelial resistance to glucagon-like peptide 1 in diabetes
Patients with diabetes may qualify for medical exemption certificates, making all prescriptions free
